Clevidipine Butyrate

丁酸氯维地平

Report date: 2024/11/08 15:29:48
NME

Base Information

Drug NameClevidipine Butyrate
Drug Alias NameclevidipinumclevidipinoCleviprexCleveloxH-324/38
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated L-type calcium channel blockers
TargetsVoltage-gated L-type calcium channel
Therapy Area/IndicationsHemorrhageHypertensionHeart Failure +[6] 
Global Approved IndicationsHypertension
Approved Indications in ChinaHypertension
Original Approved Country/TerritoryUnited States
Original Approved Date2008/08/01
Country/TerritoryUnited StatesGermanyFrance +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesThe Medicines Company
China Registration ClassN/A

Develop Information

Active CompaniesChiesi Usa IncPromedica SrlCspc Heibei Zhongrun Pharmaceutiacl Co Ltd +[4] 
Inactive CompaniesThe Medicines Company
Active IndicationsHypertensionStroke
Inactive IndicationsHemorrhageHeart FailureSubarachnoid Hemorrhage +[4] 

Other Information

ATC CodeC08CA16
Related LinksWikipediaDrugBankKEGG